Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

INTRODUCTION: In clinical trials with hepatitis C virus-infected treatment-naïve (TN) patients with compensated cirrhosis (CC), glecaprevir/pibrentasvir (G/P), a fixed-dose, once-daily, pangenotypic regimen, has demonstrated sustained virologic response at posttreatment Week 12 (SVR12) > 95%. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornberg, Markus, Ahumada, Adriana, Aghemo, Alessio, Andreoni, Massimo, Bhagat, Abhi, Butrymowicz, Isabel, Carmiel, Michal, Chodick, Gabriel, Conway, Brian, Song, Yanna, Gasbarrini, Antonio, Hüppe, Dietrich, Plaza, Francisco Jorquera, Lampertico, Pietro, Alonso, Maria Luisa Manzano, Myles, Lindsay, Persico, Marcello, Ramji, Alnoor, Sarrazin, Christoph, Villa, Erica, Weil, Clara, Otano, Juan Isidro Uriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239949/
https://www.ncbi.nlm.nih.gov/pubmed/35543964
http://dx.doi.org/10.1007/s12325-022-02158-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239949/
https://www.ncbi.nlm.nih.gov/pubmed/35543964
http://dx.doi.org/10.1007/s12325-022-02158-6

Ejemplares similares